RITE AID CORP Stock: price and insider trades · United States · SEC (Form 4)

About RITE AID CORP

RITE AID CORP (ticker RAD) is a long-standing U.S. pharmacy retailer listed on the NYSE/NASDAQ and incorporated in the United States. The company traces its roots back to 1962, when it opened its first store in Scranton, Pennsylvania under the Thrif D Discount Center name; it later adopted the Rite Aid Corporation name in 1968. Over time, Rite Aid built a recognizable neighborhood drugstore model centered on prescription fulfillment, convenience retail, and consumer health products. For decades, the company grew into one of the better-known pharmacy chains in the United States, expanding across both the East Coast and West Coast through organic growth and acquisitions. Its business model historically combined retail pharmacy with front-end merchandise, including over-the-counter medicines, wellness and beauty products, personal care items, seasonal goods, and other everyday convenience categories. Rite Aid also previously operated adjacent pharmacy-services businesses, including a PBM platform through Elixir, which it later sold. The company has used private-label and proprietary consumer brands as part of its merchandising strategy, reinforcing repeat visits and margin support in lower-ticket health-and-wellness categories. Geographically, Rite Aid historically operated a large national store network with a strong community-based footprint. The company relocated its headquarters from Camp Hill to Philadelphia’s Navy Yard district, reflecting a strategic effort to modernize its operating platform and corporate presence. Its competitive positioning has long been shaped by intense rivalry from CVS, Walgreens, supermarkets, and mass merchants, all of which exert pressure on prescription economics, front-end traffic, and store-level productivity. Recent developments are overwhelmingly defined by financial distress and restructuring. In May 2025, Rite Aid filed for a second Chapter 11 bankruptcy after its earlier turnaround failed to stabilize the business. Subsequent reporting indicated widespread store closures and the sale of pharmacy assets to competitors in a court-supervised process. As a result, the investment case has shifted from traditional retail-pharmacy growth analysis to a restructuring and liquidation framework, where asset sales, creditor recoveries, and the orderly transfer of prescription files became the primary drivers of value. For investors, Rite Aid is best viewed as a distressed U.S. healthcare-retail situation rather than a normal going-concern growth story. Its listing on the NYSE/NASDAQ and its U.S. domicile remain relevant, but the fundamental narrative is now dominated by bankruptcy proceedings, asset disposition, and residual-value uncertainty.